Response to antiviral therapy in liver transplant recipients with recurrent hepatitis C viral infection: A single center experience

Clinical Transplantation

Volumn 24, Issue 1, 2010, Pages 104-111

  Jain, Ashok ^a   Sharma, Rajeev ^a   Ryan, Charlotte ^b   Safadjou, Saman ^a   Kashyap, Randeep ^a   Mantry, Parvez ^c   Maliakkal, Benedict ^b   Orloff, Mark ^a  

^a Department of Surgery   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c METHODIST DALLAS MEDICAL CENTER   (United States)

Author keywords

Hepatitis C virus; Interferon; Liver transplant; Recurrence; Ribavirin; Viral hepatitis

Indexed keywords

CYCLOSPORIN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PREDNISOLONE; RIBAVIRIN; TACROLIMUS;

ADULT; ANEMIA; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECURRENCE; RETROSPECTIVE STUDIES; RIBAVIRIN; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 74949083503     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.00961.x     Document Type: Article

References (42)

1. Berenguer M, Ferrell L, Watson J. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000, 32:673.
2. Feray C, Caccamo L, Alexander GJ. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999, 117:619.
3. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003, 9:S28.
4. Ghobrial RM, Farmer DG, Baquerizo A. Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg 1999, 229:824.
5. Paik SW, Tan HP, Klein AS, Boitnott JK, Thuluvath PJ. Outcome of orthotopic liver transplantation in patients with hepatitis C. Dig Dis Sci 2002, 47:450.
6. Sanchez-Fueyo A, Restrepo JC, Quinto L. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 2002, 73:56.
7. Berenguer M, Palau A, Fernandez A. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006, 12:1067.
8. Mukherjee S, Lyden E. Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series. Hepatogastroenterology 2006, 53:561.
9. Neff GW, O'Brien CB, Cirocco R. Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing. Liver Transpl 2004, 10:595.
10. Bacon BR. Managing hepatitis C. Am J Manag Care 2004, 10(2 Suppl.):S30.
11. Camma C, Licata A, Cabibbo G, Latteri F, Craxi A. Treatment of hepatitis C: critical appraisal of the evidence. Expert Opin Pharmacother 2005, 6:399.
12. Everson GT, Hoefs JC, Seeff LB. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology 2006, 44:1675.
13. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002, 8:350.
14. Neuberger J. Treatment of hepatitis C virus infection in the allograft. Liver Transpl 2003, 9:S101.
15. Teixeira R, Menezes EG, Schiano TD. Therapeutic management of recurrent hepatitis C after liver transplantation. Liver Int 2007, 27:302.
16. Firpi RJ, Abdelmalek MF, Soldevila-Pico C. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002, 8:1000.
17. Lavezzo B, Franchello A, Smedile A. Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin. J Hepatol 2002, 37:247.
18. Rodriguez-Luna H, Khatib A, Sharma P. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation 2004, 77:190.
19. Wright TL. How can we identify better those with recurrent hepatitis C who will respond to therapy? What are the optimal treatment regimen and treatment duration? Liver Transpl 2003, 9:S109.
20. Gomori G. A rapid one-step trichrome stain. Am J Clin Pathol 1950, 20:661.
21. Ishak K, Baptista A, Bianchi L. Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22:696.
22. Bosch O, Tapia L, Quiroga JA, Carreno V. An escalating dose regime of recombinant interferon-alpha 2A in the treatment of chronic hepatitis C. J Hepatol 1993, 17:146.
23. Di Bisceglie AM, Martin P, Kassianides C. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989, 321:1506.
24. Perrillo RP, Schiff ER, Davis GL. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990, 323:295.
25. Saez-Royuela F, Porres JC, Moreno A. High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: a randomized, controlled trial. Hepatology 1991, 13:327.
26. Picciotto A, Varagona G, Valle F, Coviello DA, Lapertosa G, Celle G. Interferon therapy in chronic hepatitis C. Evaluation of a low dose maintenance schedule in responder patients. J Hepatol 1993, 17:359.
27. Fried MW, Shiffman ML, Reddy KR. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975.
28. Manns MP, McHutchison JG, Gordon SC. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958.
29. Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004, 40:669.
30. Ross AS, Bhan AK, Pascual M, Thiim M, Benedict Cosimi A, Chung RT. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transplant 2004, 18:166.
31. Shakil AO, McGuire B, Crippin J. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology 2002, 36:1253.
32. Narayanan Menon KV, Poterucha JJ, El-Amin OM. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl 2002, 8:623.
33. Jain AB, Eghtesad B, Venkataramanan R. Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection. Liver Transpl 2002, 8:1007.
34. Picciotto FP, Tritto G, Lanza AG. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007, 46:459.
35. Carrion JA, Navasa M, Garcia-Retortillo M. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007, 132:1746.
36. Chalasani N, Manzarbeitia C, Ferenci P. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005, 41:289.
37. Kornberg A, Hommann M, Tannapfel A. Long-term combination of interferon alfa-2b and ribavirin for hepatitis C recurrence in liver transplant patients. Am J Transplant 2001, 1:350.
38. Oton E, Barcena R, Moreno-Planas JM. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose PEG-interferon and ribavirin. Am J Transplant 2006, 6:2348.
39. Abdelmalek MF, Firpi RJ, Soldevila-Pico C. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2004, 10:199.
40. Bizollon T, Pradat P, Mabrut JY. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant 2005, 5:1909.
41. Regev A, Berho M, Jeffers LJ. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002, 97:2614.
42. Polyak SJ, Paschal DM, McArdle S, Gale MJ, Moradpour D, Gretch DR. Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication. Hepatology 1999, 29:1262.